Pages: 1 2

Advisers Ask FDA to Approve Celebrex for Juvenile Rheumatoid Arthritis

Peggy Peck
Reviewed by Zalman S. Agus, MD; Emeritus Professor at the University of Pennsylvania School of Medicine. | November 30, 2006

Bextra (valdecoxib), a Cox-2 drug marketed by Pfizer, was withdrawn in the first quarter of 2005 when it, too, was linked to increased risk of cardiovascular events.

Pages: 1 2

TOPIC INDEX

FROM PHYSICIANS PRACTICE

Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.

Improving Care Coordination in Your Practice
Susanne Madden, June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.

Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler, June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.

Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate, June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.

iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.

Advisers Ask FDA to Approve Celebrex for Juvenile Rheumatoid Arthritis

Join the Conversation